- Home
- APLT vs DXLG Comparison
APLT vs DXLG Comparison
Compare APLT & DXLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- DXLG
- Stock Information
- Founded
- APLT 2016
- DXLG 1976
- Country
- APLT United States
- DXLG United States
- Employees
- APLT N/A
- DXLG N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- DXLG Clothing/Shoe/Accessory Stores
- Sector
- APLT Health Care
- DXLG Consumer Discretionary
- Exchange
- APLT Nasdaq
- DXLG Nasdaq
- Market Cap
- APLT 63.6M
- DXLG 55.4M
- IPO Year
- APLT 2019
- DXLG 1987
- Fundamental
- Price
- APLT $0.41
- DXLG $1.41
- Analyst Decision
- APLT Buy
- DXLG Strong Buy
- Analyst Count
- APLT 6
- DXLG 1
- Target Price
- APLT $6.10
- DXLG $2.50
- AVG Volume (30 Days)
- APLT 771.9K
- DXLG 216.3K
- Earning Date
- APLT 11-06-2025
- DXLG 08-27-2025
- Dividend Yield
- APLT N/A
- DXLG N/A
- EPS Growth
- APLT N/A
- DXLG N/A
- EPS
- APLT N/A
- DXLG N/A
- Revenue
- APLT $121,000.00
- DXLG $447,744,000.00
- Revenue This Year
- APLT N/A
- DXLG N/A
- Revenue Next Year
- APLT $5,931.24
- DXLG $3.56
- P/E Ratio
- APLT N/A
- DXLG N/A
- Revenue Growth
- APLT N/A
- DXLG N/A
- 52 Week Low
- APLT $0.30
- DXLG $0.90
- 52 Week High
- APLT $10.62
- DXLG $3.10
- Technical
- Relative Strength Index (RSI)
- APLT 38.50
- DXLG 56.66
- Support Level
- APLT $0.40
- DXLG $1.20
- Resistance Level
- APLT $0.46
- DXLG $1.52
- Average True Range (ATR)
- APLT 0.03
- DXLG 0.08
- MACD
- APLT -0.01
- DXLG 0.01
- Stochastic Oscillator
- APLT 7.74
- DXLG 65.62
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.